

Metabolic Control and Progression of Retinopathy

The Diabetes in Early Pregnancy Study

EMILY Y. CHEW, MD
 JAMES L. MILLS, MD
 BOYD E. METZGER, MD
 NANCY A. REMALEY, MS
 LOIS JOVANOVIĆ-PETERSON, MD
 ROBERT H. KNOPP, MD
 MARY CONLEY, MA

LAWRENCE RAND, MD
 JOE L. SIMPSON, MD
 LEWIS B. HOLMES, MD
 JEROME H. AARONS, MD
 NATIONAL INSTITUTE OF CHILD HEALTH
 AND HUMAN DEVELOPMENT DIABETES IN
 EARLY PREGNANCY STUDY

OBJECTIVE — To evaluate the role of metabolic control in the progression of diabetic retinopathy during pregnancy.

RESEARCH DESIGN AND METHODS — We conducted a prospective cohort study of 155 diabetic women in the Diabetes in Early Pregnancy Study followed from the periconceptional period to 1 month postpartum. Fundus photographs were obtained shortly after conception (95% within 5 weeks of conception) and within 1 month postpartum. Glycosylated hemoglobin was measured weekly during the 1st trimester and monthly thereafter.

RESULTS — In the 140 patients who did not have proliferative retinopathy at baseline, progression of retinopathy was seen in 10.3, 21.1, 18.8, and 54.8% of patients with no retinopathy, microaneurysms only, mild nonproliferative retinopathy, and moderate-to-severe nonproliferative retinopathy at baseline, respectively. Proliferative retinopathy developed in 6.3% with mild and 29% with moderate-to-severe baseline retinopathy. Elevated glycosylated hemoglobin at baseline and the magnitude of improvement of glucose control through week 14 were associated with a higher risk of progression of retinopathy (adjusted odds ratio for progression in those with glycohemoglobin ≥ 6 SD above the control mean versus those within 2 SD was 2.7; 95% confidence interval was 1.1–7.2; $P = 0.039$).

CONCLUSIONS — The risk for progression of diabetic retinopathy was increased by initial glycosylated hemoglobin elevations as low as 6 SD above the control mean. This increased risk may be due to suboptimal control itself or to the rapid improvement in metabolic control that occurred in early pregnancy. Excellent metabolic control before conception may be required to avoid this increase in risk. Those with moderate-to-severe retinopathy at conception need more careful ophthalmic monitoring, particularly if their diabetes was suboptimally controlled at conception.

From the Division of Biometry and Epidemiology, National Eye Institute (E.Y.C., N.A.R.), and the Epidemiology Branch, National Institute of Child Health and Human Development (J.A.M., M.C.), National Institutes of Health, Bethesda, Maryland; Northwestern University Medical School (B.E.M.), Chicago, Illinois; Sansum Medical Research Foundation (L.J.-P.), Santa Barbara, California; Northwest Lipid Research Clinic (R.H.K.), University of Washington, Seattle, Washington; Medical Eye Associates (L.R.), Norwood, Massachusetts; Baylor College of Medicine (J.L.S.), Houston, Texas; Brigham and Women's Hospital (L.B.H.), Boston, Massachusetts; and Magee Women's Hospital (J.H.A.), Pittsburgh, Pennsylvania.

Address correspondence and reprint requests to Emily Y. Chew, MD, National Institutes of Health, Building 31, Room 6A52, 31 Center Dr., MSC 2510, Bethesda, MD, 20892-2510.

Received for publication 9 August 1994 and accepted in revised form 11 January 1995.

DCCT, Diabetes Control and Complications Trial; DIEP, Diabetes in Early Pregnancy Study; hCG, human chorionic gonadotropin; IDDM, insulin-dependent diabetes mellitus.

Metabolic control in early pregnancy has been suggested to be an important risk factor for progression of retinopathy in women with diabetes (1). However, objective retinal evaluation at conception and delivery and concurrent detailed metabolic data have not been available to test this hypothesis. It is important to determine the relationship between metabolic control and progression of retinopathy because pregnancy has been one of the few clinical situations in which aggressive attempts at metabolic normalization have been routinely instituted since even before the release of the Diabetes Control and Complications Trial results (2). Several retrospective (3–5) and prospective studies (6–10) have documented the observation that good glycemic control at conception is associated with reduced rates of spontaneous abortions and infant malformations. In addition, previous studies have also suggested that the physiological changes of pregnancy may influence the rate of progression of diabetic retinopathy (11–17).

The National Institute of Child Health and Human Development's Diabetes in Early Pregnancy Study (DIEP) provided an opportunity to examine progression of retinopathy during pregnancy and associated risk factors for progression. Women with and without diabetes were enrolled in the study before or within 21 days of conception. Stereoscopic fundus photographs were performed at the beginning and the end of the pregnancy only for the women with diabetes. Subjects were monitored extensively throughout pregnancy; thus, it was possible to examine the relationship between glucose control during early pregnancy and progression of diabetic retinopathy.

RESEARCH DESIGN AND METHODS

The DIEP was a multi-center collaborative study conducted in clinical centers at Cornell University, Brigham and Women's Hospital (Harvard

Table 1—Baseline characteristics of women with and without protocol fundus photographs

	With protocol photos	Missing or no photos	P value
n	155	189	
Race			0.9
White	147 (94.8)	179 (94.7)	
Black	5 (3.2)	5 (2.7)	
Other	3 (1.9)	5 (2.7)	
Education			0.8
High school or below	31 (20.0)	33 (17.5)	
Some college	55 (35.5)	61 (32.3)	
College degree	39 (25.2)	52 (27.5)	
Graduate school	30 (19.4)	43 (22.8)	
Prior pregnancies			0.96
None	51 (32.9)	65 (34.4)	
1	50 (32.3)	60 (31.8)	
≥2	54 (34.8)	64 (33.9)	
Prior live births			0.5
None	50 (48.1)	59 (47.6)	
1	42 (40.4)	56 (45.2)	
≥2	12 (11.5)	9 (7.3)	
Initial glycosylated hemoglobin			0.005
≤2 SD	52 (33.5)	77 (40.7)	
>2 SD, ≤4 SD	41 (26.5)	57 (30.2)	
>4 SD, ≤6 SD	31 (20.0)	33 (17.5)	
>6 SD, ≤8 SD	16 (10.3)	20 (10.6)	
>8	15 (9.7)	2 (1.1)	
Smoking			0.3
Yes	28 (18.1)	26 (13.8)	
No	127 (81.9)	163 (86.2)	
Alcohol consumption			0.5
Yes	39 (25.2)	53 (28.0)	
No	116 (74.8)	136 (72.0)	
Age (years)	27.8 ± 4.1	28.1 ± 4.0	0.4
Duration of diabetes (years)	11.9 ± 7.0	11.7 ± 6.6	0.8
Systolic blood pressure (mmHg)	110.0 ± 9.6	109.1 ± 11.6	0.2
Diastolic blood pressure (mmHg)	69.8 ± 7.5	69.5 ± 8.5	0.8
Fasting blood glucose (mg/l)	143.2 ± 57.3	144.7 ± 60.9	0.8

Data are n (%) or means ± SD.

University), Northwestern University, the University of Pittsburgh, and the University of Washington. The National Institute of Child Health and Human Development was the data and coordinating center. The primary goals of the DIEP were to assess whether pregnant women with insulin-dependent diabetes mellitus (IDDM) had an increased risk of sponta-

neous abortion and whether metabolic control affected the rates of malformation in infants of diabetic mothers.

The study design has been described in detail previously (18). Briefly, women with IDDM and nondiabetic control women were enrolled before (86%) or within 21 days of conception (14%). To ensure accurate dating of pregnancy,

subjects were encouraged to use basal body temperature monitoring; 57% did so. In all subjects, serum levels of intact or β -human chorionic gonadotropin (β -hCG) were measured 2 days after the expected 1st day of menstruation if menstruation had not begun. If the β -hCG value was equivocal, the test was repeated until a result indicating pregnancy was obtained or vaginal bleeding occurred and a negative result was obtained. Once the diagnosis of pregnancy was established, the women with diabetes were evaluated weekly during the 1st trimester and then monthly for the remainder of the pregnancy. Fundus photographs of seven standard stereo fields were obtained immediately after the diagnosis of pregnancy. Patients were followed until 1 month after the end of the pregnancy, and follow-up fundus photographs were performed either at delivery or within 1 month postpartum.

Grading of fundus photographs

Fundus photographs were centrally evaluated by the Fundus Reading Center of the University of Wisconsin, using the final scale of the Modified Airlie House Diabetic Retinopathy Classification (19). The protocol for the grading of the photographs was similar to that of the Early Treatment Diabetic Retinopathy Study (19). Each eye was evaluated by a trained grader who had no knowledge of the medical data of the patient, and eyes were categorized into the following clinical groups:

- No retinopathy.
- Microaneurysms or blot hemorrhages only.
- Mild nonproliferative retinopathy: microaneurysms and retinal hemorrhages (less than standard photograph 2A of the Diabetic Retinopathy Study [20]) and the questionable presence of hard exudates, soft exudates, intraretinal microvascular abnormalities, and/or venous beading.
- Moderate nonproliferative retinopathy: microaneurysms and intraretinal hemorrhages greater than or equal to stan-




Figure 1—The progression rates of diabetic retinopathy stratified by baseline retinopathy. Patients with more severe diabetic retinopathy were more likely to show progression than those with no retinopathy at baseline (χ^2 for trend, $P < 0.001$). NPDR, nonproliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.

standard photograph 2A in more than three fields, microaneurysms and intraretinal hemorrhages greater than or equal to standard photograph 2A, and the definite presence of hard exudate, soft exudates, intraretinal microvascular abnormalities, and/or venous abnormalities in one field.

- Severe nonproliferative retinopathy: same as moderate nonproliferative retinopathy with lesions found in two or more fields of the standard seven fields of the fundus photographs.
- Proliferative retinopathy: presence of retinal neovascularization.

The photographs from both the baseline and postdelivery visits were independently assessed. Each of the seven standard fields of the fundus photographs was examined for all retinal lesions. A summary measure of all these fields was determined for each eye. For each patient, gradings for both eyes were combined for assessment along this scale. A two-step

change along this grading scale was considered to be clinically significant. Progression to proliferative retinopathy was also a clinically important end point. Patients with proliferative retinopathy or evidence of previous scatter photocoagulation for proliferative retinopathy at baseline were not included in the analyses for risk factors for progression of retinopathy.

Assessment of metabolic control during early pregnancy

Glycosylated hemoglobin was measured using a thiobarbituric acid colorimetric method, which allowed all analyses to be performed in a central laboratory with frozen, washed red cells (21). The results are reported as SD from the mean of the nondiabetic DIEP control population. Glycosylated hemoglobin was assessed weekly during the 1st trimester and monthly thereafter. The initial glycosy-

lated hemoglobin level was determined between 4 and 7 weeks after the last menstrual period in 95% of the subjects.

Statistical analysis

Comparison of variables expressed as proportions were performed with the χ^2 test. A χ^2 test of trend was also used. Logistic regression analysis was used to evaluate risk factors associated with progression of retinopathy during pregnancy (22).

RESULTS— Of the 386 women with diabetes enrolled in the study periconceptionally, 42 had fetal losses. Of the remaining 344 women, 87 did not have any fundus photographs taken, 102 had one of the two required sets of photographs (77 had only baseline photographs and 25 had only postpartum photographs), and 155 had photographs both in early pregnancy and after delivery. Comparison of the socioeconomic and medical characteristics of women who had both fundus photographs with those of women who had either no fundus photographs or only one set of photographs showed that women who had both fundus photographs had higher glycosylated hemoglobin levels at entry ($P = 0.005$) (Table 1). The two groups did not differ significantly in any other risk factor. The baseline level of retinopathy in patients who had only baseline photographs was similar to that in those who had both baseline and follow-up photographs ($P = 0.45$).

Rates of progression of diabetic retinopathy

The following analysis is based on the 140 women for whom both baseline and postdelivery photographs were available. Fifteen additional patients who had both baseline and postdelivery photographs were excluded from the analysis because they had proliferative retinopathy at baseline or had previously received scatter photocoagulation for proliferative retinopathy. Figure 1 displays the progression rates (≥ 2 -step change) of retinopathy during pregnancy in 140 patients

Table 2—Univariate analysis of potential risk factors for progression of diabetic retinopathy

	Progression		Odds ratio	(95% confidence interval)	P value
	No	Yes			
n	106	34			
Baseline hemoglobin 6 SD above control mean	106	34	2.4	(1.01–5.91)	0.048
Baseline retinopathy					0.001
No retinopathy (reference)	35	4	1.0	—	
Microaneurysms only	30	8	2.3	(0.6–8.5)	
Mild NPDR	26	6	2.0	(0.5–7.9)	
Moderate NPDR	15	16	9.3	(2.7–32.6)	
Gravidity					0.18
0 (reference)	30	15	1.0	—	
1	35	9	0.5	(0.2–1.3)	
2	25	3	0.2	(0.1–0.9)	
3	11	4	0.7	(0.2–2.7)	
≥4	5	3	1.2	(0.3–5.7)	
Smoker					0.07
No (reference)	90	24	1.0	—	
Yes	16	10	2.3	(0.9–5.8)	
Age (5-year increase)	106	34	1.0	(0.7–1.7)	0.88
Duration of diabetes					<0.001
1–5 years (reference)	37	2	1.0	—	
6–10 years	25	4	3.0	(0.5–17.4)	
11–15 years	19	10	9.7	(1.9–49.0)	
16–20 years	16	13	15.0	(3.0–74.5)	
>20 years	9	5	10.3	(1.7–61.8)	
Blood pressure (10-mmHg increase)	106	34	1.3	(0.8–2.2)	0.31
Proteinuria (mg/24 h)					0.06
0–150 (reference)	87	23	1.0	—	
151+	11	8	2.8	(1.0–7.6)	

The initial glycosylated hemoglobin level was evaluated as an ordered scale, resulting in a comparison of the value of 6 SD above the control mean with that of the diabetic subjects within the normal range of 2 SD from the control mean. For every 10-mmHg increase in the systolic blood pressure, there was an odds ratio of 1.3 (95% confidence interval 0.8–2.2). NPDR, nonproliferative diabetic retinopathy.

stratified by baseline retinopathy. The risk of progression increased with increasing severity of retinopathy at baseline. A two-step or greater progression or development of proliferative retinopathy was seen in 10.3, 21.1, 18.8, and 54.8% of patients with no retinopathy, microaneurysms only, mild nonproliferative retinopathy, and moderate or more severe nonproliferative retinopathy at baseline, respectively. Patients with no retinopathy or only microaneurysms at conception did not develop proliferative retinopathy. Of those patients with mild and moderate retinopathy at baseline, progression to proliferative diabetic retinopathy was seen in 2 of 32 (6.3%) and 9 of 31 (29%),

respectively. Approximately 25% of these patients had high-risk proliferative diabetic retinopathy, as defined by the Diabetic Retinopathy Study (23).

Risk factors for progression of diabetic retinopathy

The following possible risk factors were examined: initial glycosylated hemoglobin level, gravidity, smoking, age, duration of diabetes, blood pressure, proteinuria, and baseline severity level of diabetic retinopathy (Table 2). Baseline severity of retinopathy ($P = 0.001$), initial glycosylated hemoglobin ($P = 0.048$) (Fig. 2), and duration of diabetes ($P < 0.001$)

were significant risk factors in this univariate analysis.

Significant factors from the univariate analyses were then placed in a stepwise multivariable logistic regression model. Increasing severity of baseline retinopathy was associated with increased risk of progression of retinopathy ($P = 0.0001$) (Table 3). Duration of diabetes was highly correlated with increasing severity of baseline retinopathy. Approximately 30% of the DIEP patients had diabetes durations of >15 years. A logistic regression model was performed to assess factors associated with progression of retinopathy and evaluate the relationship between severity of baseline retinopathy




Figure 2—The unadjusted progression rates of diabetic retinopathy (≥ 2 steps) and 95% confidence intervals by baseline glycosylated hemoglobin values in SD from the control mean. Patients with higher levels of glycosylated hemoglobin were at greater risk of progression (χ^2 test for trend, $P = 0.05$). The DIEP values expressed in SD correspond to the following values used in the DCCT scale: ≤ 2 SD: 6.05%; $>2, \leq 4$ SD: 6.05–7.05%; $>4, \leq 6$ SD: 7.05–8.05%; $>6, \leq 8$ SD: 8.05–9.05%; >8 SD: 10.05%.

and duration of diabetes (<15 years vs. >15 years). Baseline retinopathy was again significant ($P = 0.025$), while duration of diabetes was not ($P = 0.10$). For subsequent determination of logistic regression models, the severity of baseline retinopathy was selected in these analyses. In additional analyses of patients with moderate or more severe retinopathy at baseline in the DIEP, retinopathy progressed by two or more steps (unadjusted) in 55% of patients with ≤ 15 years of diabetes and 50% of patients with >15 years of diabetes. However, when the rates of development of proliferative retinopathy were compared in patients stratified by duration of diabetes, retinopathy progressed to this stage in 39% of patients with >15 years of diabetes but in only 18% of patients with durations of ≤ 15 years. Thus, duration of diabetes may not be the most important factor for progression of retinopathy, but it may be significant in the development of proliferative retinopathy.

An elevated glycosylated hemoglobin level at baseline was associated with a higher risk of progression of retinopathy (Fig. 2). Initial glycosylated hemoglobin measurements were evaluated as ordered variables along a scale. For example, women with baseline glycosylated hemoglobin 6 SD above the control mean (8.05% in the DCCT) had an odds ratio of

2.7 (95% confidence interval 1.1–7.2) when compared with women with baseline glycosylated hemoglobin levels within 2 SD of the control mean. Patients in whom retinopathy was most likely to progress had both the poorest control at baseline and the largest improvement during early pregnancy (Fig. 3). It was impossible to separate these two aspects of glucose control with these data because in virtually all patients, poor initial control of diabetes improved during pregnancy.

CONCLUSIONS— The DIEP is the first study to include a relatively large number of women with both fundus photographs and detailed metabolic data shortly after conception to assess the effect of metabolic control on retinopathy. The DIEP data showed that the patients in whom retinopathy was most likely to progress had the poorest control of their diabetes at conception. Moreover, in women with less than adequate control of their diabetes, i.e., glycosylated hemoglobin levels >6 SD above the control mean, rates of progression of retinopathy almost doubled, especially if retinopathy was present at conception. Those DIEP patients who had moderate or more severe retinopathy at conception were at significantly greater risk for progression. Patients with no retinopathy or only microaneurysms at conception had a low risk

Table 3—Risk factors for progression of retinopathy in the multivariable logistic regression model

	Odds ratio	95% confidence interval	P value
Baseline retinopathy			<0.001
Mild NPDR or less	1.0	—	
Moderate NPDR	5.7	2.1–15.7	
Initial glucose control ≥ 6 SD above control mean	2.7	1.1–7.2	0.039

For the multivariable results, variables are considered in stepwise analysis: glucose control, baseline retinopathy, duration of diabetes. The initial glycosylated hemoglobin level was evaluated as an ordered scale, resulting in a comparison of the value of 6 SD above the control mean with that of the diabetic subjects within the normal range of 2 SD from the control mean. NPDR, nonproliferative diabetic retinopathy.




Figure 3—First trimester glycosylated hemoglobin levels with 95% confidence intervals in patients who experienced progression of diabetic retinopathy by ≥ 2 steps (—) and in patients who did not show progression by ≥ 2 steps (- - -).

for progression, as previously reported by Phelps et al. (1).

The rates of progression of retinopathy in the DIEP were compared with the first annual rates of progression in the Diabetes Control and Complications Trial (DCCT). The DIEP rates of ≥ 2 steps of worsening in retinopathy were significantly higher than those found in both the experimental treatment (intensive treatment, $P = 0.007$) and the control group of the DCCT ($P < 0.001$). The development of proliferative retinopathy was significantly higher in the DIEP when compared with the DCCT intensive treatment group ($P = 0.04$) and with the conventional treatment group ($P = 0.047$). In some respects, the DCCT population is a suitable group for comparison because the two populations were similar in the severity of retinopathy at baseline and the fundus photographs were graded at the same fundus reading center using the same classifications of retinopathy. The main disadvantage of using the DCCT data for comparison is that the duration of diabetes of DCCT subjects is shorter than that of the DIEP subjects. Limiting the

analyses of this study to patients with ≤ 15 years of diabetes left insufficient power for comparisons with the DCCT subjects.

It is possible that the duration of diabetes may not be as important a risk factor for ≥ 2 -step progression of retinopathy as baseline retinopathy severity is, but duration of diabetes may be a more important risk factor for the development of proliferative retinopathy.

Progression of retinopathy seen in the DIEP may also be explained in part by the improvement of glucose control in early pregnancy. Progression of retinopathy after institution of tight control has been clearly documented in nonpregnant subjects (24–26). The data from the DCCT showed that subjects randomly assigned to the tight metabolic control arm of the study experienced an increased risk of progression of retinopathy within the first 2 years. In the DIEP, the effect of the institution of tight glycemic control is difficult to separate from the effect of elevated glycosylated hemoglobin levels at conception because patients who were most likely to have progression had both

the poorest control at baseline and the largest improvement during early pregnancy. These two variables are highly correlated in both this study and clinical practice. A further confounding factor is the correlation of increasing severity of retinopathy with increasing poor glucose control at baseline.

The DIEP results have important clinical implications. Women with moderate or more severe retinopathy at conception are at a greater risk of progression of retinopathy during pregnancy. Patients with significant retinopathy who have suboptimal metabolic control at conception are at greatest risk for progression. Proliferative diabetic retinopathy may develop, and careful ophthalmic monitoring is indicated. The routine practice of instituting tight glycemic control in early pregnancy may also contribute to worsening retinopathy. However, numerous studies indicate that good diabetic control around the time of conception and throughout organogenesis reduces the risks of spontaneous abortion and malformation (13–17). Furthermore, the long-term beneficial effects of sustained tight glucose control include a reduction of retinopathy by as much as 50–70% at 7 years of follow-up (2). We suggest that women with diabetes who are contemplating pregnancy but have less than adequate control of their diabetes (i.e., glycosylated hemoglobin >6 SD above the control mean) should be brought into tight glycemic control before conception, especially if retinopathy is present. Improving metabolic control before pregnancy to prevent progression of retinopathy offers the best opportunity for a favorable outcome for the mother and the infant.

Acknowledgments—This work was supported in part by Grants CRC R0047, RR-48, and RR-00037–28 from the U.S. Public Health Service.

The authors wish to thank Drs. Frederick L. Ferris III and Matthew D. Davis for their helpful advice and the DCCT Research Group for their collaboration of data.

References

1. Phelps RL, Sakol P, Metzger BE, Jampol LM, Freinkel N: Changes in diabetic retinopathy during pregnancy: correlations with regulation of hyperglycemia. *Arch Ophthalmol* 104:1806–1810, 1986
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329:977–986, 1993
3. Miller E, Hare JW, Cloherty JP, Dunn PJ, Gleason RE, Soeldner JS, Kitzmiller JL: Elevated maternal hemoglobin A_{1c} in early pregnancy and major congenital anomalies in infants of diabetic mothers. *N Engl J Med* 304:1331–1334, 1981
4. Leslie RDG, Pyke DA, John PN, White JM: Hemoglobin A_{1c} in diabetic pregnancy. *Lancet* ii:958–959, 1978
5. Ylinen K, Aula P, Stenman U-H, Kesaniemi-Kuokkanen T, Teramo K: Risk of minor and major fetal malformations in diabetics with high hemoglobin A_{1c} values in early pregnancy. *Br Med J* 289:345–346, 1984
6. Fuhrmann K, Reiher H, Semmler K, Fischer F, Fischer M, Glockner E: Prevention of congenital malformations in infants of insulin-dependent diabetic mothers. *Diabetes Care* 6:219–223, 1983
7. Fuhrmann K, Reiher H, Semmler K, Glockner E: The effect of intensified conventional insulin therapy before and during pregnancy on the malformation rate in offspring of diabetic mothers. *Exp Clin Endocrinol* 83:173–177, 1984
8. Steel JM: Prepregnancy counseling and contraception in the insulin-dependent diabetic patient. *Clin Obstet Gynecol* 28: 553–66, 1984
9. Mills JL, Simpson JL, Driscoll SG, Jovanovic-Peterson L, Van Allen M, Aarons JH, Metzger B, Bieber FR, Knopp RH, Holmes LB, Peterson CM, Withiam-Wilson M, Brown Z, Ober C, Harley E, MacPherson TA, Duckles A, Mueller-Heubach E, National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study: Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. *N Engl J Med* 319:1617–1623, 1988
10. Mills JL, Knopp RH, Simpson JL, Jovanovic-Peterson L, Metzger BE, Holmes LB, Aaron JH, Brown Z, Reed GF, Bieber FR, Van Allen M, Holzman I, Ober C, Peterson CM, Withiam MJ, Duckles A, Mueller-Heubach E, Polk BF, National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study: Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. *N Engl J Med* 318:671–676, 1988
11. Rodman HM, Singerman LJ, Aiello LM, Merkatz IR: Diabetic retinopathy and its relationship to pregnancy. In *The Diabetic Pregnancy? A Perinatal Perspective*. Merkatz ER, Adams PAJ, Eds. New York, Grune & Stratton, 1979
12. Jervell J, Moe N, Skjaeraasen J, Blystad W, Egge K: Diabetes mellitus and pregnancy: management and results at Rikshospitalet, Oslo 1970–1977. *Diabetologica* 16: 151–155, 1979
13. Dibble CM, Kochenour NK, Worley RJ, Tyler FH, Swartz M: Effect of pregnancy on diabetic retinopathy. *Obstet Gynecol* 59:699–704, 1982
14. Soubrane G, Canivet J, Coscas G: Influence of pregnancy on the evolution of background retinopathy. *Int Ophthalmol Clin* 8:249–255, 1985
15. Moloney JBM, Drury IM: The effect of pregnancy on the natural course of diabetic retinopathy. *Am J Ophthalmol* 93: 745–56, 1982
16. Klein BEK, Moss SE, Klein R: Effect of pregnancy on progression of diabetic retinopathy. *Diabetes Care* 13:34–40, 1990
17. Stephens JW, Page OC, Hare RL: Diabetes and pregnancy: a report of experiences in 119 pregnancies over a period of ten years. *Diabetes* 12:213–219, 1963
18. Mills JL, Fishl AR, Knopp RH, Ober CL, Jovanovic LG, Polk BF: Malformations in infants of diabetic mothers: problems in study design. *Prev Med* 12:274–286, 1983
19. Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification: ETDRS Report Number 10. *Ophthalmology* 98:786–806, 1991
20. The Diabetic Retinopathy Study Research Group: DRS Report 7: a modification of the Airlie House Classification of Diabetic Retinopathy. *Invest Ophthalmol Vis Sci* 21: 210–226, 1981
21. Pecoraro RE, Graf RJ, Halter JB, Beiter H, Porte DJr: Comparison of colorimetric assay for glycosylated hemoglobin with ion-exchange chromatography. *Diabetes* 28: 1120–1125, 1979
22. Hosmer DW, Lemeshow S: *Applied Logistic Regression*. New York, Wiley, 1989
23. The Diabetic Retinopathy Study Research Group: Four risk factors for severe visual loss in diabetic retinopathy: the third report from the Diabetic Retinopathy Study. *Arch Ophthalmol* 97:654–655, 1979
24. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T: Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. *Lancet* i:200–204, 1983
25. Kroc Collaborative Study Group: Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial. *N Engl J Med* 311:365–372, 1984
26. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O: Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. *Br Med J* 290:811–815, 1985